Recursion Pharmaceuticals, Enamine release new tools in its AI/ML platform

Recursion announced the generation of screening libraries leveraging tools within its AI/ML platform, the Recursion OS, with Enamine’s REAL Space, the world’s largest source of make-on-demand small molecules. Together, the two companies have curated 10 enriched screening libraries from over 15,000 newly synthesized compounds designed to accelerate drug discovery against 100 key and clinically relevant drug targets in difficult to address biological areas. “We have been using the Recursion OS to identify compounds across Enamine’s vast chemical space for our own internal discovery needs,” said Chris Gibson Co-Founder and CEO of Recursion. “This collaboration allows us to extend that approach to areas of biology that are of general interest to the industry. We are bringing together the best of both worlds-Enamine’s vast chemical library and Recursion’s AI-driven drug discovery platform to help expand the drug discovery toolset.”